维普期刊资源整合服务平台（V6.5）

84篇 您的检索式：作者名="SCALTRITI M"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	The epidermal growth factor receptor pathway:a model for targeted therapy显示文摘	Scaltriti M Baselga J	2006	Clin Cancer Res2006，12，：	1
2	Nuclear translocation of a clusterin isoform is associated with induction of anioikis in SV40-immortalized human prostate epithelial cell显示文摘	Caccamo AE Scaltriti M Caporali A		0，，：	1
3	Expression of p95 HER-2,a truncated form of the HER-2 receptor,and response to anti-HER-2 therapies in breast cancer显示文摘	Scaltriti M Rojo F Ocana A		0，，08：	1
4	Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER-2 receptor显示文摘	Scaltriti M Chandarlapaty S Prudkin L		0，，：	1
5	Loss of HER-2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes显示文摘	Mittendorf EA Wu Y Scaltriti M	2009	Clin Cancer Res2009，15，23：	1
6	Phosphatidylinositol 3- kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 显示文摘	Eichhorn P J Gili M Scaltriti M	2008	Cancer Res2008，68，92：	1
7	Biosynthesis of tumorigenic HER2 C - terminal fragments by alternative initiation of translation 显示文摘	Anido J Scaltriti M Bech Serra J J	2006	Embo J2006，25，13：	1
8	Cyclin E amplification/over expression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients显示文摘	Scaltriti M Eichhom PJ Cortés J		0，，：	1
9	Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells显示文摘	SCALTRITI M SANTAMARIA A PACIUCCI R	2004	Cancer Res2004，64，17：	1
10	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab- dependent cell cytotoxicity 显示文摘	Scaltriti M Verma C Guzman M	2009	Oncogene2009，28，6：	1
11	NVPBEZ235,a dual PI3K/mTOR inhibitor prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations显示文摘	SERRRA V MARMAN B SCALTRITI M	2008	Cancer Res2008，68，19：	1
12	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER-2 + breast cancer patients显示文摘	Scaltriti M Eichhom PJ Cortés J		0，，：	1
13	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients显示文摘	SCALTRITI M EICHHORN PJ CORT(E)S J		0，，：	1
14	The epidermal growth factor receptor pathway:a model for targeted therapy显示文摘	Scaltriti M Baselga J	2006	Clin Cancer Res2006，12，18：	1
15	Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 ( Her2 ) from colocalization : an in silico based mech- anism显示文摘	Fuentes G Scaltriti M Baselga J	2011	Breast Cancer Res2011，13，3：	1
16	The epidermal growth factor receptor path- way:a model for targeted therapy显示文摘	Scaltriti M Baselga J	2006	Clin Cancer Res2006，12，：	1
17	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer显示文摘	Serra V Scaltriti M Prudkin L	2011	Oncogene2011，30，22：	1
18	NVP- BEZ235, a dual PBK/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations 显示文摘	SERRA V MARKMAN B SCALTRITI M	2008	Cancer Res2008，68，19：	1
19	NVP-BEZ235,a dual PI3K/mTOR inhibitor,prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations显示文摘	Serra V Markman B Scaltriti M	2008	Cancer Res2008，68，：	1
20	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235显示文摘	Eichhorn PJ Gili M Scaltriti M	2008	Cancer Res2008，68，：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示